Clovis Oncology, Inc.s in-depth stock price analysis indicates that the stock price has rallied 76.69% in the past 12 Weeks , but analyzing the 6 month charts for the stock , the price continues to stay positive and keep the rally at 172.7% . Looking at the past 52 week period, the stock price is up at 232.79% . Relative price strength is a important factor used by wealth management firms while investing in stocks because the indicator compares the stock performance with the overall market. The relative price strength of Clovis Oncology, Inc. has a positive value of 131.35 compared to overall market. Clovis Oncology, Inc. (NASDAQ:CLVS) has tumbled 1.8% during the past week, however, the bigger picture is still very bullish; the stocks have advanced and posted positive gains of 13.83% in the last four weeks. The stocks have underperformed the S&P 500 by 2.6% during the past week but Clovis Oncology, Inc. (NASDAQ:CLVS) it has outperformed the index in 4 weeks by 11.79%.
Clovis Oncology, Inc. (NASDAQ:CLVS) stock ended Friday session in the red zone in a volatile trading. The stock closed down 2 points or 3.07% at $63.13 with 1,379,436 shares getting traded. Post opening the session at $64.89, the shares hit an intraday low of $63.13 and an intraday high of $64.99 and the price was in this range throughout the day. The company has a market cap of $2,799 million and the number of outstanding shares has been calculated to be 44,335,662 shares. The 52-week high of Clovis Oncology, Inc. (NASDAQ:CLVS) is $67.16 and the 52-week low is $11.57.
Clovis Oncology Inc Last issued its quarterly earnings results on Nov 3, 2016. The company reported $-1.70 EPS for the quarter, beating the analyst consensus estimate by $ 0.25. Analyst had a consensus of $-1.95.During the same quarter in the previous year, the company posted $-2.62 EPS.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Clovis Oncology Inc was Downgraded by Chardan Capital Markets on Feb 3, 2017 to Sell, Price Target of the shares are set at $36.Clovis Oncology Inc was Initiated by BofA/Merrill on Jan 27, 2017 to Buy, Price Target of the shares are set at $74.Clovis Oncology Inc was Upgraded by Piper Jaffray to Overweight on Jan 26, 2017. Company shares were Reiterated by Stifel on Jan 23, 2017 to Buy, Raises Price Target to $ 86 from a previous price target of $52 .Clovis Oncology Inc was Initiated by Morgan Stanley to Overweight on Jan 13, 2017.
Company has reported several Insider transactions to the SEC, on Nov 3, 2015, Erle T Mast (Executive VP and CFO) sold 3,000 shares at 104.18 per share price.On Oct 30, 2015, Lindsey Rolfe (officer ) sold 4,000 shares at 97.80 per share price.On Oct 16, 2015, Gillian C Ivers-read (officer ) sold 3,000 shares at 91.91 per share price.
Clovis Oncology Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. The Company targets its development programs for the treatment of specific subsets of cancer populations. Clovis Oncology Inc. is headquartered in Colorado, USA.